DNLI vs. IMCR, TWST, ACLX, IOVA, SWTX, VCEL, RXRX, APGE, KYMR, and ADMA
Should you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Immunocore (IMCR), Twist Bioscience (TWST), Arcellx (ACLX), Iovance Biotherapeutics (IOVA), SpringWorks Therapeutics (SWTX), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), and ADMA Biologics (ADMA). These companies are all part of the "biological products, except diagnostic" industry.
Denali Therapeutics (NASDAQ:DNLI) and Immunocore (NASDAQ:IMCR) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking.
Denali Therapeutics presently has a consensus price target of $40.22, suggesting a potential upside of 96.11%. Immunocore has a consensus price target of $81.85, suggesting a potential upside of 53.59%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Denali Therapeutics is more favorable than Immunocore.
In the previous week, Immunocore had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 20 mentions for Immunocore and 19 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.49 beat Immunocore's score of 0.13 indicating that Denali Therapeutics is being referred to more favorably in the media.
Immunocore has lower revenue, but higher earnings than Denali Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.
Immunocore has a net margin of -22.60% compared to Denali Therapeutics' net margin of -36.51%. Denali Therapeutics' return on equity of -11.46% beat Immunocore's return on equity.
Denali Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
Denali Therapeutics received 391 more outperform votes than Immunocore when rated by MarketBeat users. However, 70.59% of users gave Immunocore an outperform vote while only 67.43% of users gave Denali Therapeutics an outperform vote.
92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 7.9% of Denali Therapeutics shares are held by company insiders. Comparatively, 9.1% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Denali Therapeutics beats Immunocore on 10 of the 18 factors compared between the two stocks.
Get Denali Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Denali Therapeutics Competitors List
Related Companies and Tools
